InsiderPulse
Dashboard

PTGX

Protagonist Therapeutics, Inc.

Health CareRussell 2000

Protagonist Therapeutics, Inc. insider trading

Protagonist Therapeutics, Inc. files with the SEC as a Pharmaceutical Preparations company headquartered in Newark, CA. Every time one of its executives or directors buys or sells the stock, the filing appears here the moment it reaches the SEC — with grants and option exercises set apart from the trades that cost the insider their own money.

From SEC filings

Recent PTGX insider transactions

7 insiders traded PTGX on the open market between Feb 17, 2026 and Sep 10, 2026 — 20 sales worth $63.4M, of which 8 were pre-scheduled under a 10b5-1 plan.

Bought
—
Sold
$63.4M

8 of 20 on a 10b5-1 plan

Net
−$63.4M
Insiders
7

Open-market purchases (code P) and sales (code S) from Protagonist Therapeutics, Inc.'s own SEC Form 4 filings. Grants and option exercises are excluded — they are compensation, not decisions. Share counts are derived from the reported value and price. Verify any figure against the original filing before acting on it; this is monitoring, not advice.

Filing history last read from EDGAR on Sep 23, 2026. The live dashboard shows new filings the moment they clear.

Every PTGX Form 4 on SEC.gov

SEC Form 4 data, Q3 2024 to Q2 2026

PTGX insider trading by quarter

Between Jul 01, 2024 and Jun 30, 2026, 8 insiders traded PTGX on the open market: 0 purchases and 56 sales worth $69.1M, 11 of the sales pre-scheduled under a 10b5-1 plan. In the last four quarters alone: 0 purchases and 37 sales ($51.2M), by 7 insiders.

QuarterBoughtSold
Q2 2026—−$16.5M9 sales · 4 on a plan
Q1 2026—−$29.5M19 sales
Q4 2025—−$1.2M3 sales · 2 on a plan
Q3 2025—−$3.9M6 sales · 2 on a plan
Q2 2025—−$1.2M3 sales
Q1 2025—−$3.6M4 sales · 1 on a plan
Q4 2024—−$11.8M8 sales
Q3 2024—−$1.3M4 sales · 2 on a plan
Largest sale
−$7.5M of PTGX by Patel Dinesh V Ph D (President and CEO · Director) on May 12, 2026, under a 10b5-1 plan.

Open-market transactions through Jun 30, 2026most recent first

  • Waddill William D.

    Director

    −$1.7M

    Feb 06, 2026

    20,000 sh · $83.68

  • Ali Asif

    Chief Financial Officer

    −$2.3M

    Jan 27, 2026

    28,000 sh · $83.13

  • Ali Asif

    Chief Financial Officer

    −$1.5M

    Jan 27, 2026

    18,203 sh · $83.14

  • Molina Arturo MD

    Chief Medical Officer

    −$410K

    Jan 27, 2026

    5,000 sh · $82.00

  • Patel Dinesh V Ph D

    President and CEO · Director

    −$338.4K

    Jan 27, 2026

    4,068 sh · $83.19

  • Patel Dinesh V Ph D

    President and CEO · Director

    −$1.2M

    Jan 26, 2026

    14,205 sh · $84.05

  • Patel Dinesh V Ph D

    President and CEO · Director

    −$897.5K

    Jan 26, 2026

    10,685 sh · $84.00

  • Molina Arturo MD

    Chief Medical Officer

    −$411.4K

    Jan 26, 2026

    5,000 sh · $82.28

  • Patel Dinesh V Ph D

    President and CEO · Director

    −$1.6M

    Jan 23, 2026

    19,315 sh · $84.59

  • Molina Arturo MD

    Chief Medical Officer

    −$1.1M

    Jan 23, 2026

    13,151 sh · $82.42

  • Patel Dinesh V Ph D

    President and CEO · Director

    −$2.8M

    Jan 20, 2026

    34,438 sh · $82.48

  • Molina Arturo MD

    Chief Medical Officer

    −$784.7K

    Jan 20, 2026

    9,514 sh · $82.48

  • Ali Asif

    Chief Financial Officer

    −$708.3K

    Jan 20, 2026

    8,588 sh · $82.48

  • Molina Arturo MD

    Chief Medical Officer

    −$229.9K

    Nov 17, 2025

    2,712 sh · $84.77

  • Waddill William D.10b5-1

    Director

    −$702.5K

    Oct 10, 2025

    8,000 sh · $87.81

From SEC's quarterly Form 3, 4 and 5 data sets: code P purchases and code S sales of common stock, by the date the trade happened. Where a fund and the people who control it each report the same block, it is counted once. Trades made in the last days of Q2 2026 but filed after it closed arrive with SEC's next quarterly release.

Protagonist Therapeutics, Inc. company record

SEC industry classification
Pharmaceutical Preparations
Headquarters
Newark, CA
Incorporated in
DE
Listed on
Nasdaq
SEC Central Index Key
0001377121
Previously filed as
Protagonist Inc

Sourced from this company's own SEC submissions record. The industry label is SEC's Standard Industrial Classification, which is more specific than the Health Care sector shown above.

After insiders bought PTGX

What the stock actually did in the 90 days following each open-market purchase

Don't check PTGX — let it ping you

Get told the moment an insider moves on PTGX

Pro watches Protagonist Therapeutics, Inc. for you and sends a Telegram ping within moments of a Form 4 clearing EDGAR — a C-suite open-market buy, a cluster, a 10b5-1 regime break — long before it reaches the press. Add PTGX to a watchlist, see each mover's benchmark-measured track record and which legendary funds hold it, and read the full filing history instead of the last 72 hours.

Track PTGX on the live dashboardFilings on SEC.gov

The live dashboard is free to open. Alerts, watchlists, full filing history and each mover's benchmark-measured track record are Pro. Monitoring, not advice.

How to read PTGX insider activity

Open-market purchase (code P)
An insider spending their own money at market price. This is the only buy code that reliably carries signal — it is a decision, not compensation.
Grants and option exercises (codes A, M)
Scheduled compensation. Most "insider buying" headlines are really this, which is why InsiderPulse weights it at a fraction of a real purchase.
Cluster buy
Two or more different insiders buying on the open market in the same window. One executive buying can mean anything; three is much harder to explain away.

Other Health Care tickers

RVMDRYTMSMMTSNDXSRRKTGTXVERAVKTXXENEZLABATTODNTH
This week on the tape: who actually chose to sellThe weekly split of scheduled 10b5-1 selling vs deliberate sales, with the deciders named.

Questions

Are PTGX insiders buying or selling?
Between Feb 17, 2026 and Sep 10, 2026, 7 Protagonist Therapeutics, Inc. insiders made no open-market purchases and 20 sales worth $63.4M, a net sale of $63.4M. 8 of the sales were pre-scheduled under a Rule 10b5-1 plan.
How much PTGX stock have insiders bought and sold in the last two years?
Between Jul 01, 2024 and Jun 30, 2026, 8 Protagonist Therapeutics, Inc. insiders made no open-market purchases and 56 sales worth $69.1M. 11 of the sales were pre-scheduled under a Rule 10b5-1 plan. In the four quarters to Jun 30, 2026: no purchases and 37 sales ($51.2M). The largest sale was Patel Dinesh V Ph D selling $7.5M on May 12, 2026.
What was the largest recent PTGX insider trade?
Patel Dinesh V Ph D (President and CEO · Director) sold $9.8M of PTGX stock on Aug 10, 2026 at about $149.11 a share, under a pre-scheduled 10b5-1 plan.
When did an insider last buy PTGX shares?
No open-market purchase by a Protagonist Therapeutics, Inc. insider appears in the filings from Feb 17, 2026 to Sep 10, 2026 — every recorded open-market transaction in that period was a sale.
Where does PTGX insider trading data come from?
From the Form 4 filings Protagonist Therapeutics, Inc.'s officers, directors and 10% owners must send the SEC within two business days of a trade. Each row on this page links to its original filing on SEC EDGAR. Share grants and option exercises are kept apart from open-market purchases and sales, because only the latter cost the insider their own money.

Get the free Insider Brief

Each weekday evening: the day's biggest open-market insider buys, cluster formations and 10b5-1 plan breaks — in plain English, with grants and routine vesting stripped out. Honest about what the data can and cannot say.

No account needed. One-click unsubscribe.